Abstract 1195P
Background
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant condition, caused by an alteration in the TP53 gene. Individuals with LFS are susceptible to developing a wide range of malignancies. National and international guidelines recommend annual WB-MRI scan for screening for cancer; however, WB-MRI is not yet implemented in this setting worldwide or in the UK. SIGNIFIED is a cost-effectiveness and implementation project that will assess the value of screening WB-MRI in LFS.
Methods
Individuals with LFS, with no cancer diagnosis in the past 5 years, were scanned using two WB-MRI, 12 months apart. Diffusion-weighted MRI images were acquired from vertex to feet. Incidental findings were further investigated and discussed in a specialist MDT meeting.
Results
Fifty-four asymptomatic individuals with LFS were recruited between May 2022 and July 2023 from Cancer Genetic Units across the United Kingdom. 40 females (74%) and 14 males (26%) were enrolled. The median age at recruitment was 42 years (range 18-70). Following 1st scan performed in 54 individuals, 16.6% of patients had a suspicious lesion that was biopsied/excised (N=9), and less than half (44%, N=4) had a confirmed cancer. Following 2nd scan performed in 44 individuals, 13.6% of patients had a suspicious lesion that was biopsied/excised (N=6) and in 83% of cases (N=5), a cancer diagnosis was confirmed. There was increased confidence in benignity when a comparator scan was available. In total, 9 cancers were detected and 66% (N=6) were diagnosed at stages 0-2 and underwent curative treatment. A further stage 3 pancreatic cancer (T4N0M0) was diagnosed and the patient received peri-operative chemotherapy and surgery with curative intent.
Conclusions
Overall, 9 cancers in 54 individuals were diagnosed with the help of WB-MRI. The rate of cancers detected in this cohort was higher than expected in a general population, consistent with the known risk of cancers in the LFS population. WB-MRI is a valuable and useful radiological tool for the detection of early cancers in LFS and our data support guidelines that it should be implemented as a regular screening test for this population. A health economics analysis is currently ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Small Business Research Initiative (SBRI) Healthcare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
697P - The Empower Pathway overview: An innovative approach to delivering personalised care for testicular cancer survivors
Presenter: Robert Holwell
Session: Poster session 09
698P - Outcomes of patients with testicular germ cell tumors in Latin-America
Presenter: Saul Campos Gomez
Session: Poster session 09
699P - Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadectomy in Metastastic Seminoma) trial: Three year update
Presenter: Axel Heidenreich
Session: Poster session 09
701P - Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)
Presenter: Hedyeh Ebrahimi
Session: Poster session 09
702P - Survival and related factors in testicular non-seminomatous patients undergoing high-dose chemotherapy and autologous stem cell transplantation: Experience of Turkey's highest volume transplantation center
Presenter: Musa Baris Aykan
Session: Poster session 09
703P - Survival of Hispanic germ cell tumor patients at a single academic institution vs. SEER
Presenter: Adam Kolawa
Session: Poster session 09
704P - Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study
Presenter: Christoph Oing
Session: Poster session 09
705P - Subsequent malignant neoplasms (SMN) in patients with germ cell tumor of the testis (TGCT): Implications on a genetic vs stem cell origin of cancers
Presenter: Sruthi Vellanki
Session: Poster session 09
706P - Stereotactic radiosurgery (SRS) in brain metastases (BMs) from non-seminomatous germ cell tumours (NSCGTs)
Presenter: Deep Chakrabarti
Session: Poster session 09